First 10 runs free
    First 10 runs free

    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer

    Resolved · regulation · Occurred · Assessed · 1 sources

    This assessment is dated 2026-09-29. Check what remains unresolved below before relying on it.

    Which companies' revenue or costs change?

    FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.

    QuestionWhat the evidence establishes
    What was reported?Reported factAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).
    What else was confirmed?Reported factThe submission targets patients with MET-driven, EGFR-mutated non-small cell lung cancer who progressed on prior EGFR-TKI therapy.
    Does the valuation support acting?UnknownNo stored valuation assumptions for HCM yet — this is the next research task.
    What would change the assessment?UnknownFDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDA

    What would this event cost your holdings?

    Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.

    Test this event against my holdings

    Public research record

    Research framework · page evidence

    Completed event assessment

    regulatory milestone achievement and future US commercial royalties

    TypeClaimScope
    AssumptionAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).2026-09-29
    Interpretationregulatory milestone achievement and future US commercial royaltiesHCM
    Countercase, invalidators, and sources
    Countercase

    FDA grants Priority Review status, accelerating US commercial launch timeline into early 2027.

    What would change the view
    • · FDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDA
    • HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer · 2026-09-29

    Get the next source update

    One email when the underlying evidence changes. No daily digest.

    What remains unresolved

    Base path
    Standard review proceeds with PDUFA action date scheduled within regular 10-month regulatory window.
    Adverse path
    FDA requests additional clinical subgroup data, delaying formal approval.
    Supportive path
    FDA grants Priority Review status, accelerating US commercial launch timeline into early 2027.
    • · FDA Filing Acceptance and PDUFA Date Assignment — Monitor 60-day day filing validation notice from the US FDAnext month

    Evidence

    • HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer2026-09-29

      “HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy.”

      Supports: AstraZeneca submitted US NDA to FDA for ORPATHYS plus TAGRISSO combination in lung cancer.